Showing 1 - 10 of 1,247
sequential rather than simultaneous innovation; (2) generate incentives that decline with the number of previous (shelved …
Persistent link: https://www.econbiz.de/10011597824
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the … treatment cost in both financing alternatives, justifying inclusion of the innovation in the benefit list from a cost …
Persistent link: https://www.econbiz.de/10003900791
Over the last two decades privatization programs in different countries radically reduced the role of the State as a key player in the economic arena. We use agency theory to discuss the theoretical relationship between changes in the firm's principal-agent structure following privatization, and...
Persistent link: https://www.econbiz.de/10011597627
Today, the global pharmaceutical product value chain is becoming increasingly complex and this has led to the emergence of 'multiple quality standards' for medicines. But this non-uniformity in the quality of medicine is also contingent upon both the regulatory milieu in the country of...
Persistent link: https://www.econbiz.de/10011337690
This article assesses how the form of the utility function in discrete-choice experiments (DCEs) affects estimates of willingness-to-pay (WTP). The utility function is usually assumed to be linear in its attributes. Non-linearities, in the guise of interactions and higher-order terms, are...
Persistent link: https://www.econbiz.de/10008702182
Elements of regulation inherent in most social health insurance systems are a uniform package of benefits and uniform cost sharing. Both elements risk to burden the population with a welfare loss if preferences differ. This suggests introducing more contracted choice; however, it is widely...
Persistent link: https://www.econbiz.de/10002202974
Health insurance is potentially subject to risk selection, i.e. adverse selection on the part of consumers and cream skimming on the part of insurers. Adverse selection models predict that competitive health insurers can eschew high-risk individuals by offering contracts with low deductibles or...
Persistent link: https://www.econbiz.de/10003216009
Regulation fostering Managed Care alternatives in health insurance is spreading. This work reports on an experiment designed to measure the amounts of compensation asked by the Swiss population (in terms of reduced premiums) for Managed-Care type restrictions in the provision of health care. It...
Persistent link: https://www.econbiz.de/10002746136
The German health care reform of 1997 provides a natural experiment for evaluating the price sensitivity of demand for physicians' services. As a part of the reform, co-payments for prescription drugs were increased step up to 200%. However, certain groups of people were exempted from the...
Persistent link: https://www.econbiz.de/10001806923
This paper reports on a re-evaluation of the German health care reform of 1997. A previous evaluation found a limited effect of a 4.4 percent reduction of the number of doctor visits in a sample of pharmacy customers. The re-evaluation based on a representative household survey, the German...
Persistent link: https://www.econbiz.de/10001807289